Status: Bibliographieeintrag
Standort: ---
Exemplare:
---
| |  Online-Ressource |
|---|
| Verfasst von: | Dengler, Jolanta [VerfasserIn]  |
|---|
| | Topaly, Julian [VerfasserIn] |
|---|
| | Frühauf, Stefan [VerfasserIn] |
|---|
| | Hensel, Manfred [VerfasserIn] |
|---|
| | Ho, Anthony Dick [VerfasserIn] |
|---|
| Titel: | Level of CD 20-expression and efficacy of Rituximab treatment in patients with resistant or relapsing B-cell prolymphocytic leukemia and B-cell chronic lymphocytic leukemia |
|---|
| Verf.angabe: | Jolanta Perz, Julian Topaly, Stefan Fruehauf, Manfred Hensel Anthony D. Ho (Department of Internal Medicine V, University of Heidelberg) |
|---|
| E-Jahr: | 2002 |
|---|
| Jahr: | [2002] |
|---|
| Umfang: | 3 S. |
|---|
| Fussnoten: | Elektronische Reproduktion der Druckausgabe ; Gesehen am 14.12.2021 |
|---|
| Titel Quelle: | Enthalten in: Leukemia and lymphoma |
|---|
| Ort Quelle: | London [u.a.] : Taylor & Francis Group, 1989 |
|---|
| Jahr Quelle: | 2002 |
|---|
| Band/Heft Quelle: | 43(2002), 1, Seite 149-151 |
|---|
| ISSN Quelle: | 1029-2403 |
|---|
| Abstract: | Rituximab (IDEC C2B8) is a chimeric human-mouse monoclonal anti-CD20 antibody that has been proven to be effective for the treatment of patients with CD20 positive leukemia and lymphoma. The level of CD20-expression in patients with B-cell chronic lymphocytic leukemia (B-CLL) is low in comparison to other B-cell lymphomas and normal B-cells. Previous experience with rituximab treatment in small series of patients with B-CLL suggest that it is less effective in B-CLL than in follicular lymphomas. We analyzed the correlation between CD20-expression level and efficacy of rituximab treatment in eight patients with refractory or relapsed B-CLL and two patients with B-cell prolymphocytic leukemia (B-PLL). We could not identify any correlation between CD20-expression and efficacy of rituximab treatment. |
|---|
| DOI: | doi:10.1080/10428190210178 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: https://doi.org/10.1080/10428190210178 |
|---|
| | DOI: https://doi.org/10.1080/10428190210178 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | Anti Cd20 Antibody |
|---|
| | B-cell Chronic Lymphocytic Leukemia (B-CLL) |
|---|
| | B-cell Prolymphocytic Leukemia (B-PLL) |
|---|
| | Cd20-expression |
|---|
| | Monoclonal Antibody |
|---|
| | Rituximab |
|---|
| K10plus-PPN: | 1782135200 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Level of CD 20-expression and efficacy of Rituximab treatment in patients with resistant or relapsing B-cell prolymphocytic leukemia and B-cell chronic lymphocytic leukemia / Dengler, Jolanta [VerfasserIn]; [2002] (Online-Ressource)
68822969
